Onodera

Executive Summary

Onodera GT Pharma is a Japanese biotechnology company pioneering gene therapies for serious neurodegenerative and monogenic disorders, leveraging adeno-associated virus (AAV) vector technology. Founded in 2020 and operating as an academic research hub, the company's lead programs target sporadic ALS and Parkinson's disease. At the preclinical stage, Onodera collaborates with researchers nationwide to advance novel treatments. The company's focus on high-unmet-need diseases and its strategic position within Japan's biotech ecosystem present a compelling opportunity, though significant clinical and regulatory milestones remain ahead. With a small team of 10-50 employees and no disclosed funding or valuation, Onodera represents an early-stage investment with high risk but potentially high reward if its gene therapy platform proves effective in human trials.

Upcoming Catalysts (preview)

• H1 2026Preclinical Proof-of-Concept Data for ALS Program50% success
• H2 2026IND Filing for Parkinson's Disease Program30% success
• 2026Strategic Partnership or Licensing Deal for AAV Platform20% success